Edition:
United States

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

67.49USD
10 Dec 2018
Change (% chg)

$-0.66 (-0.97%)
Prev Close
$68.15
Open
$69.22
Day's High
$69.85
Day's Low
$65.93
Volume
3,032,738
Avg. Vol
2,417,733
52-wk High
$89.53
52-wk Low
$64.27

Latest Key Developments (Source: Significant Developments)

Gilead Sciences Says CEO Daniel O'Day Will Get Annual Base Pay Of $1.6 Mln
Monday, 10 Dec 2018 04:12pm EST 

Dec 10 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC - DANIEL O'DAY WILL RECEIVE AN ANNUAL BASE SALARY OF $1.6 MILLION - SEC FILING.  Full Article

Gilead Sciences Plans To Hire Daniel O'Day As Its Next CEO - WSJ
Sunday, 9 Dec 2018 08:30pm EST 

Dec 9 (Reuters) - :DRUGMAKER GILEAD SCIENCES PLANS TO HIRE DANIEL O'DAY AS ITS NEXT CEO - WSJ, CITING SOURCES.  Full Article

Galapagos Phase 3 Data On Filgotinib In Biologic-Experienced Rheumatoid Arthritis
Saturday, 20 Oct 2018 06:30pm EDT 

Oct 22 (Reuters) - GALAPAGOS NV ::REPORTED TOGETHER WITH GILEAD SCIENCES ON SUNDAY PHASE 3 DATA ON FILGOTINIB IN BIOLOGIC-EXPERIENCED RHEUMATOID ARTHRITIS.FINCH 2 STUDY RESULTS DEMONSTRATE SIGNIFICANT IMPROVEMENT IN RHEUMATOID ARTHRITIS SIGNS, SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE.DATA SUGGEST FILGOTINIB HAS A POTENTIAL ROLE IN ADDRESSING IMPORTANT UNMET NEEDS IN THE TREATMENT OF RHEUMATOID ARTHRITIS.POSITIVE EFFICACY DATA FROM FINCH 2 WERE PREVIOUSLY ANNOUNCED IN SEPTEMBER 2018.ADDITIONAL FINCH 2 DATA TO BE PRESENTED INCLUDE POSITIVE RESULTS ACROSS SEVERAL PATIENT-REPORTED HEALTH-RELATED QUALITY OF LIFE MEASURES.FILGOTINIB DEMONSTRATED A SAFETY PROFILE CONSISTENT WITH EARLIER CLINICAL TRIALS.  Full Article

Walgreens Boots On Wage Increase Says Remain Confident With Offer They Have At Local Level; "We Will Remain A Very, Very Competitive Employer"
Thursday, 11 Oct 2018 10:08am EDT 

Oct 11 (Reuters) - Walgreens Boots Alliance Inc ::CFO SAYS TAKING ACTIONS TO ADDRESS U.K. RETAIL PERFORMANCE, AND CO WILL BE INVESTING IN THE NEW STORE AND DIGITAL CONTENT - CONF CALL.WALGREENS BOOTS ON WAGE INCREASE SAYS REMAIN CONFIDENT WITH THE OFFER THEY HAVE AT LOCAL LEVEL; "WE WILL REMAIN A VERY, VERY COMPETITIVE EMPLOYER" - CONF CALL.WALGREENS ON WAGE INCREASE SAYS "AMAZON PRIMARILY RECRUITS PEOPLE WHO WALK IN, IN WAREHOUSES ... THAT IS QUITE DIFFERENT IN TERMS OF MARKET RATES".WALGREENS ON GILEAD SCIENCES’S AUTHORIZED GENERICS STRATEGY SAYS “OPEN TO ANYTHING THAT REDUCES COST FOR CUSTOMER”, CALLS IT GOOD MOVE FOR INDUSTRY.WALGREENS CEO ON REIMBURSEMENT RATE PRESSURE AFTER PBM DEALS SAYS “WHAT WE CAN PERCEIVE TODAY, IT'S MORE FAVORABLE THAN NEGATIVE”.  Full Article

Gilead, Galapagos Announce Tortuga Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint
Thursday, 6 Sep 2018 01:01am EDT 

Sept 6 (Reuters) - Galapagos NV : :GILEAD AND GALAPAGOS ANNOUNCE TORTUGA PHASE 2 STUDY OF FILGOTINIB IN ANKYLOSING SPONDYLITIS ACHIEVES PRIMARY ENDPOINT.ADVERSE EVENTS GENERALLY MILD OR MODERATE IN SEVERITY AND WERE REPORTED IN EQUAL PROPORTION OF PATIENTS IN FILGOTINIB AND PLACEBO GROUPS.  Full Article

Gilead Enters Licensing Agreement With Trianni For Use Of Trianni Transgenic Human Monoclonal Antibody Discovery Platform
Tuesday, 4 Sep 2018 04:05pm EDT 

Sept 4 (Reuters) - Gilead Sciences Inc ::GILEAD ENTERS LICENSING AGREEMENT WITH TRIANNI FOR USE OF TRIANNI TRANSGENIC HUMAN MONOCLONAL ANTIBODY DISCOVERY PLATFORM.GILEAD SCIENCES INC - NO FINANCIAL DETAILS WERE DISCLOSED.  Full Article

Sierra Oncology Acquires Momelotinib From Gilead Sciences
Wednesday, 22 Aug 2018 07:00am EDT 

Aug 22 (Reuters) - Sierra Oncology Inc ::SIERRA ONCOLOGY ACQUIRES MOMELOTINIB, AN INVESTIGATIONAL JANUS KINASE (JAK) 1/2 AND ACTIVIN RECEPTOR TYPE 1 (ACVR1) INHIBITOR FOR MYELOFIBROSIS, FROM GILEAD SCIENCES.SIERRA ONCOLOGY INC - WILL PAY GILEAD A $3 MILLION UPFRONT FEE FOR MOMELOTINIB AND POTENTIAL AGGREGATE MILESTONE PAYMENTS OF UP TO $195 MILLION.SIERRA ONCOLOGY INC - SIERRA WILL ASSUME ALL CURRENTLY ONGOING CLINICAL STUDIES WITH MOMELOTINIB FOLLOWING A TRANSITION PERIOD..SIERRA - TO ALSO PAY GILEAD ROYALTIES ON ANY SALES OF MOMELOTINIB, WHICH WILL BE TIERED BASED ON COMMERCIAL SUCCESS & RANGE FROM MID-TEENS TO HIGH-TWENTIES.  Full Article

Gilead Sciences Says China Drug Administration Approves Epclusa
Wednesday, 30 May 2018 01:00am EDT 

May 30 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC - CHINA DRUG ADMINISTRATION APPROVES EPCLUSA(SOFOSBUVIR/VELPATASVIR), GILEAD'S PAN-GENOTYPIC TREATMENT FOR CHRONIC HEPATITIS C VIRUS INFECTION.GILEAD SCIENCES INC - EPCLUSA IS FIRST PAN-GENOTYPIC HCV SINGLE TABLET REGIMEN (STR) APPROVED IN CHINA..  Full Article

Gilead: Natco And Teva Requested FDA Permission To Make Generic Version Of Sovaldi - SEC Filing
Tuesday, 27 Feb 2018 06:41am EST 

Feb 27 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC SAYS IN FEBRUARY 2018, CO RECEIVED NOTICES FROM NATCO PHARMA LIMITED AND TEVA PHARMA - SEC FILING.GILEAD SCIENCES INC - NATCO PHARMA LIMITED,TEVA EACH SUBMITTED ANDA TO FDA REQUESTING PERMISSION TO MANUFACTURE AND MARKET GENERIC VERSION OF SOVALDI.GILEAD SCIENCES - TEVA ALLEGES THAT NINE PATENTS ASSOCIATED WITH SOFOSBUVIR INVALID, UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY TEVA’S MANUFACTURE.GILEAD SCIENCES-NATCO PHARMA ALLEGES THAT TWO PATENTS ASSOCIATED WITH SOFOSBUVIR INVALID,UNENFORCEABLE AND/OR WILL NOT BE INFRINGED BY NATCO’S MANUFACTURE.  Full Article

EMA Says Gilead Pulls Application To Extend Use Of Zydelig Drug ‍​
Friday, 23 Feb 2018 07:25am EST 

Feb 23 (Reuters) - EU MEDICINES AGENCY :APPLICATION TO EXTEND USE OF GILEAD SCIENCES ZYDELIG DRUG FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITHDRAWN ‍​‍​.  Full Article

Photo

Gilead Sciences snares Roche veteran O'Day as CEO

Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.